Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives - Bill of Health
Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives - Bill of Health
Are the incentive mechanisms for orphan drug development working as they should?
FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
Abuses of Government Programs and Regulations - Drug Pricing Lab
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies - KFF Health News
Abuses of Government Programs and Regulations - Drug Pricing Lab
Eight pharma trends for 2022: towards a more holistic understanding of value - Pharmaceutical Technology
Incentives Provided by the Orphan Drug Act – BIO
Health Justice as the Lodestar of Incremental Health Reform - Bill of Health
Drugs For Rare Diseases Have Become Uncommonly Rich Monopolies
Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives - Bill of Health
Pharmaceutical policy and innovation for rare
13. Incentivising the Development of Global Public Goods for Health, Ready for the Next Crisis? Investing in Health System Resilience
